Black Diamond Therapeutics Inc (BDTX)
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on discovering and developing MasterKey therapies for patients with genetically defined tumors. Its lead candidate, silevertinib, is a brain-penetrant epidermal growth factor receptor (EGFR) MasterKey inhibitor being studied in Phase 2 trials for EGFR mutant non-small cell lung cancer and glioblastoma. The company is also advancing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor designed to target KRAS, NRAS, and BRAF alterations in solid tumors, currently in Phase 1 testing. Another program, BDTX-4876, is a preclinical MasterKey inhibitor directed at oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. Formerly known as ASET Therapeutics, Inc., the company adopted its current name in January 2018 and was incorporated in 2014. It is headquartered in Cambridge, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BDTX
|
$1.86
|
-6.3% Downside
|
Fair
|
$10
|
405.1% Upside
|
Bargain
|
Fair
|
0.0%
|
November 9, 2026
|
1.2x
|
113.8 M
|
18.499 M
|
13.2%
|
91.6%
|
-3.3
|
77.2%
|
